CAMBRIDGE, Mass., Jan. 29 /PRNewswire-FirstCall/ -- Transkaryotic
Therapies, Inc. (Nasdaq: TKTX) today announced that as part of its strategic
plan to market and sell Replagal(TM) (agalsidase alfa) enzyme replacement
therapy for the treatment of Fabry disease in Canada upon regulatory approval,
Paul McCabe has been named Country Manager. Mr. McCabe joins TKT from
Pharmacia Canada Inc. where he held the position Director, Oncology Business
Unit and led sales and marketing activities for this business in Canada. In
this newly created position, Mr. McCabe will have overall responsibility for
Replagal sales and marketing initiatives, including managing product
development and reimbursement.
In his role as Director of the Oncology Business Unit at Pharmacia Canada,
Mr. McCabe oversaw many product launches, including CAMPTOSAR(R), a leading
chemotherapeutic in Canada. Prior to joining Pharmacia Canada, Mr. McCabe held
positions of increasing responsibility in sales and marketing at Lederle
Laboratories and Cyanamid Canada, Inc. Mr. McCabe received a B.Sc. (Agr.) from
the University of Guelph and an MBA from the University of Western Ontario.
"Paul's successful track-record in pharmaceutical marketing and sales,
including several product launches, will be of tremendous value to us as we
prepare for TKT's first commercial product launch outside of Europe for
Replagal," said Michael J. Astrue, President and Chief Executive Officer of
TKT.
In January 2004, TKT expanded its operations in Canada, opening an office
in Toronto. All Canadian correspondence should be directed to: TKT Canada
Inc., 120 Eglinton Avenue East, Suite 1000, Toronto, Ontario, Canada M4P 1E2,
telephone 416-322-2886.
About TKT
Transkaryotic Therapies, Inc. is a biopharmaceutical company committed to
developing treatments for rare diseases caused by protein deficiencies with a
core focus on lysosomal storage diseases. The company markets one product,
Replagal(TM), an enzyme replacement therapy for Fabry disease in Europe and
other countries and is developing treatments for Hunter syndrome and Gaucher
disease. TKT's research pipeline is focused on rare diseases where a
significant unmet medical need exists. TKT was founded in 1988 and is
headquartered in Cambridge, Massachusetts, with additional operations in
Europe, Canada and Latin America. Additional information about TKT is
available on the company's website at http://www.tktx.com.
This press release contains forward-looking statements, including
statements regarding the potential approval and launch of Replagal in Canada,
as well as statements containing the words "believes," "anticipates," "plans,"
"expects," "estimates," "intends," "should," "could," "will," "may," and
similar expressions. There are a number of important factors that could cause
the company's actual results to differ materially from those indicated by such
forward-looking statements, including whether Replagal will be approved in
Canada for commercial use; whether reimbursement will be successfully obtained
in various Canadian provinces; the impact of competing products on the
Canadian market for the treatment of Fabry disease; and other factors set
forth under the caption "Risk Factors" in the company's Quarterly Report on
Form 10-Q for the quarter ended September 30, 2003, which is on file with the
Securities and Exchange Commission and are incorporated herein by reference.
While the company may elect to update forward-looking statements at some point
in the future, the company specifically disclaims any obligation to do so,
even if its expectations change.
Replagal(TM) is a trademark of Transkaryotic Therapies, Inc. CAMPTOSAR(R)
is a registered trademark of Pharmacia Canada Inc.
CONTACTS:
Justine E. Koenigsberg
Director, Corporate communications
(617) 349-0271
Daniella M. Lutz
Corporate Communications Specialist
(617) 349-0205
SOURCE Transkaryotic Therapies, Inc.
 back to top
Related links:
http://www.tktx.com
Photo Notes:
NewsCom:
http://www.newscom.com/cgi-bin/prnh/19990913/TKTLOGO
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, 888-776-6555 or 212-782-2840
Company News On-Call:
http://www.prnewswire.com/comp/120657.html
CONTACT:
Justine E. Koenigsberg, Director, Corporate
communications, +1- 617-349-0271; or Daniella M. Lutz, Corporate
Communications Specialist, +1- 617-349-0205, both of
Transkaryotic Therapies, Inc.
|
